New hope for liver cancer patients: cabozantinib safety trial shows promise

NCT ID NCT03963206

Completed Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe the drug cabozantinib is for people with advanced liver cancer (hepatocellular carcinoma) who have already tried another treatment called sorafenib. A total of 110 adults took part. The main goal was to see how long patients lived after starting cabozantinib and to track any side effects that required changing the dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Show contact details

Locations

APHM - Timone

Marseille, France
APHP - Hôpital St Antoine

Paris, France
CHRU Rennes site pontchaillou

Rennes, France
CHRU de Lille-Hôpital Claude Huriez

Lille, France
CHU Amiens Picardie - Hôpital Sud

Amiens, France
CHU Dupuytren

Limoges, France
CHU Jean Minjoz

Besançon, France
CHU Toulouse PURPAN

Toulouse, France
CHU de St Etienne

Saint-Priest-en-Jarez, France
Centre Hospitalier Universitaire de Montpellier

Montpellier, France
Centre Hospitalier de Boulogne sur mer

Boulogne-sur-Mer, France
Centre hospitalier universitaire Côte de nacre

Caen, France
Hospices Civils de Lyon - Hôpital de la Croix Rousse

Lyon, 69004, France
Hôpital Avicenne

Bobigny, France
Hôpital Beaujon

Clichy, France
Hôpital Brabois adulte - CHU de Nancy

Vandœuvre-lès-Nancy, France
Hôpital Robert Debré - CHU de Reims

Reims, France
Hôpital haut- lévêque

Pessac, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.